Branched-chain amino acid transferase 2 (BCAT2) deficiency: A case series and systematic review.
分岐鎖アミノ酸転移酵素2(BCAT2)欠損症:症例シリーズと系統的レビュー (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- その他の原著論文
- 対象
- 未確定
- 出版年
- 2026
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/03
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
BCAT2欠損症は分岐鎖アミノ酸(BCAA)異化を障害する常染色体劣性疾患であるが、報告が少なく臨床像や代謝特徴は不明である。本研究ではスロベニアの新規3症例を報告し、系統的レビューで既報8例を加えた計11例を解析した。3症例は全てNM_001190.4:c.600C>A(p.Tyr200Ter)変異のホモ接合体で、バリン濃度は794〜2589μmol/L。症状は頭痛、発達遅延、知的障害を呈した1例のみで、他は無症状だった。1例にインスリン抵抗性を認め、BCAA高値との関連が示唆された。既報例では知的障害が55%、発達遅延や神経症状が36%にみられ、画像検査を受けた全例で白質異常を認めた。ピリドキシン補充で全例BCAAが低下したが、臨床改善は50%のみだった。BCAT2欠損症は無症状から重症の神経障害まで多様であり、病原性は不明確である。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Background: Branched-chain amino acid transaminase 2 (BCAT2) deficiency is an autosomal recessive disorder that impairs branched-chain amino acid (BCAA) catabolism. Its clinical and metabolic features remain poorly understood due to limited reports in the literature.Methods: We report three novel cases of BCAT2 deficiency from Slovenia: one diagnosed following symptom onset, one through cascade screening of parents, and one by newborn screening. Diagnosis was established through metabolic evaluation and confirmation of pathogenic variants in the BCAT2 gene. In addition, we performed a systematic review of all previously reported cases of BCAT2 deficiency.Results: All three patients were homozygous for the NM_001190.4:c.600C > A (p.Tyr200Ter) variant, with valine concentrations at presentation of 2093, 2589, and 794 μmol/L. Only one patient was symptomatic, presenting with headaches, developmental delay, and intellectual disability, while the remaining two were largely asymptomatic. Notably, insulin resistance was observed in one of the three patients and may be associated with elevated BCAA levels. Systematic literature review identified 8 additional cases of BCAT2 deficiency. Genetic variant c.600C > A was also found in two Pakistani individuals, while the remaining variants were each reported in only a single individual. The most common clinical characteristics were intellectual disability (55%), developmental delay and other neurological symptoms (36%). Abnormal white matter findings on MRI were observed in all patients who underwent imaging. BCAA levels decreased in all patients receiving pyridoxine supplementation; however, only 50% showed clinical improvement.Conclusion: BCAT2 deficiency displays marked interindividual heterogeneity, ranging from asymptomatic cases to severe neurological impairment, which renders its pathogenicity uncertain.
DOI 10.1016/j.ymgmr.2026.101291
PMID 41623317
原文・出典を見る →